In comparison to anti-CD47 or anti-PDL1 monotherapy or anti-CD47 + anti-PDL1 combinational therapy, simultaneously targeting both CD47 and PDL1 on tumor cells with a CD47/PDL1 bispecific antibody delivered the best tumor growth inhibition and prolonged recipient survival (94, 95). This evidence concerns the gene CD47 and neoplasm.